The Lancet Gastroenterology & Hepatology
@LancetGastroHep
Followers
26K
Following
2K
Media
3K
Statuses
9K
The Lancet Gastroenterology & Hepatology is the world-leading #gastroenterology and #hepatology research journal. IF=30.9.
Joined February 2016
We are the world-leading gastroenterology and hepatology research journal. While a partial measurement of our impact, we are pleased to share our Impact Factor of 30·9 and CiteScore of 50·3.
1
3
26
Ambitious targets by @WHO have been established to eliminate #viralhepatitis by 2030. New Commission provides scorecard of national progress to ascertain progress of high-burden countries towards these targets - #nohep
5
135
735
#Free for #UEGWeek - the microbiota–gut–brain axis in #obesity - #microbiome #microbiota @jfcryan @TedDinan
7
199
346
New @TheLancet - Adam et al - Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet trial). #CRCSM #LiverTwitter
2
118
272
New Review - Hagstrom et al - Natural history and progression of metabolic dysfunction-associated steatotic liver disease. #LiverTwitter #MASLD @hanneshagstrom @patriknasr @yingshang1
0
93
270
Viral #hepatitis is a major public health threat and a leading cause of death worldwide, killing 1·34 million people every year, similar numbers to deaths from HIV/AIDS, tuberculosis, or malaria—new Commission - #nohep
5
122
206
New Review online — NASH drug treatment development: challenges and lessons, by Tilg, Byrne and Targher. A wide range of mechanisms are being studied; ideal #NASH candidates should be safe and hepatoprotective+cardioprotective.#MASLD #MASH #LiverTwitter
0
89
229
New @TheLancet Series on functional gastrointestinal disorders (disorders of gut-brain interaction) - #UEGWeek #gitwitter #FGID #DGBI #IBS #dyspepsia
4
77
189
New Review - Targher et al - Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. #NAFLD #MAFLD #fattyliver #livertwitter
0
51
176
New Review - Targher et al - Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. #livertwitter #NAFLD #MAFLD #fattyliver
0
81
175
New Review - Nuzzo et al - Prevention and treatment of nutritional complications after bariatric surgery. #gitwitter @AlexandreNuzzo @franciscajoly #bariatricsurgery #obesity
3
86
177
New Commission sets out priorities at national, regional, and global levels to accelerate progress towards elimination of #viralhepatitis by 2030 - #nohep
1
32
141
New Review - Elkrief et al - Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies. @ERN_RARE_LIVER @ValdigGroup #LiverTwitter @RautouE
3
73
155
New online - Lu et al - International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement. . #GITwitter #IBD @IBD_FloMD
1
66
148
Review: The microbiota–gut–brain axis in #obesity - - #free for #WorldObesityDay #microbiome #microbiota
3
89
142
New research - Reynolds et al - Trimodality therapy vs perioperative chemotherapy for locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS phase 3 trial. #OncTwitter #GITwitter #EsoCSM
2
74
143
New research - Liu et al - Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. #GITwitter #OncTwitter @OncoAlert
5
82
137
New online - Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. @IHPBA @gbonneysurg @eahpba @_ilts_. #livertwitter #APHPBA_2021
2
82
129
New Correspondence: Prolonged presence of #SARSCoV2 viral RNA in faecal samples - #gitwitter #COVID19
3
108
134
New research - Loomba et al - Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. #NASH #NAFLD #cirrhosis #gitwitter #livertwitter #medtwitter @DrLoomba
5
52
126
New research - Haifer et al - Lyophilised oral faecal microbiota transplantation for #ulcerativecolitis (LOTUS): a randomised, double-blind, placebo-controlled trial. #GITwitter #IBD #microbiome #microbiota #FMT @rupertleong
2
41
120
New Review - @MonicaTincopa & @drloomba - Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. #NASH #NAFLD #fattyliver #livertwitter
4
47
119
The #mesentery as an organ in its own right: its structure, function, and role in #gastrointestinal disease #free
6
131
114
Neoadjuvant #immunotherapy for locally advanced dMMR/MSI-H #colorectalcancer resulted in pathological complete response in a high proportion of patients, according to new research. Read more here: #crcsm #GITwitter
0
46
109
A selection of highlights from @LancetGastroHep over the past 12 months - a mix of our most read, most discussed, and Editors' favourites 👉👉👉. #GITwitter #LiverTwitter
3
33
111
Although effective treatments for #hepC exist, many individuals cannot access these drugs due to restrictions on reimbursements. Here’s a recent overview of such restrictions in Europe - #nohep #worldhepatitisday
5
52
98
New Review - Quality standards for the management of non-alcoholic fatty liver disease (#NAFLD): consensus recommendations from the @BASLedu & @BritSocGastro NAFLD Special Interest Group. #fattyliver #livertwitter
3
46
106
This week's issue of @TheLancet features a new Seminar on #liver #cirrhosis from Pere Ginès and colleagues - #LiverTwitter
0
42
103
New Editorial - Herbal and dietary supplements: unregulated hepatotoxicity. #LiverTwitter #DILI
1
37
102
A thread of our #COVID19 #gastroenterology & #hepatology related content . 1. Comment - Yeo et al - Enteric involvement of coronaviruses: is faecal–oral transmission of #SARSCoV2 possible? (Feb 19, 2020) . #gitwitter #livertwitter.
3
58
100
New research - Siriwardena et al - A procalcitonin-based algorithm to guide antibiotic use in patients with acute #pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial . #acutepancreatitis #GITwitter #AMR @MFT_MRI @MFTnhs
1
45
99
New Review - The relationship between gastrointestinal cancers and the microbiota. #gitwitter #microbiota #gastrointestinal #cancer @fredhutch
0
46
97
New Review - Piano et al - Infections in cirrhosis . #LiverTwitter #IDTwitter #Cirrhosis @salvatore_piano @sebas_marciano
1
45
98
Comment on new Commission: Civil society’s critical role in the elimination of #viralhepatitis - @Hep_Alliance @RaqPeck #nohep
0
20
85
Comment on new Commission: Elimination of #viralhepatitis by 2030: ambitious, but achievable - #nohep
0
17
85
New Review - Duijzer et al - Clinical management of liver cyst infections: an international, modified Delphi-based clinical decision framework. #LiverTwitter
1
32
94
New research - van der Does de Willebois et al - Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised trial. #GITwitter #IBD
4
48
95
Out now - results from the @PROFILECrohn trial, a biomarker-stratified comparison of top-down vs accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease. . #GITwitter #IBD #ECCO24 #ECCO2024
3
41
93
New Review - Tranah et al - Diagnosis and management of ectopic varices in portal hypertension. #LiverTwitter @ThomasTranah @DavidPatch1 @dtrip2015 @DebbieShawcros1 @TheBileDoc @SarahHughesHep
0
30
91
NEW Review online, exploring epidemiological to mechanistic evidence on the health effects of ultra-processed foods #UPF #GITwitter.@BenoitChassaing @BernardSrour @m_dch @BonazziErica @melissa_kordahi
1
60
89
New research - Aggressive fluid hydration plus NSAIDs versus NSAIDs alone for post-ERCP pancreatitis - the FLUYT trial. #gitwitter #ERCP #pancreatitis @pancreatitis_nl @joostphdrenth @MarcBesselink @rcverdonk @PaulFockens @christasw
4
43
90
New online @TheLancet - Amitriptyline at Low-Dose and Titrated for #IBS as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Catch the #UEGWeek presentation this pm by @alex_ford12399 .
0
45
82
Check out a review on management of the multiple symptoms of #irritablebowelsyndrome - #free for #UEGWeek #IBS #FGID
3
43
76
New Review - Parigi et al - Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. #GITwitter #IBD @silvio_silvio75 @PeyrinBiroulet @ibddocmaria @vipuljairath @IBDMD @IOIBD1
2
31
75
Our latest issue is now live at Includes content on #alcohol, #IBD, #Hpylori, #HCV, #training, #livertransplantation + more!. #livertwitter #gitwitter #medtwitter #transplanttwitter
1
19
77
5
71
74
New Review - Guillo et al - Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the IOIBD. @IOIBD1 @PeyrinBiroulet @silvio_silvio75 #IBD #GITwitter
0
37
73
Hartmann’s procedure versus sigmoidectomy with primary anastomosis for perforated #diverticulitis with purulent or faecal peritonitis (LADIES): a randomised trial - #colorectalresearch #colorectalsurgery #SoMe4Surgery
1
52
76
New research - @teoh_anthony et al - Endoscopic ultrasonography-guided gastroenterostomy versus uncovered duodenal metal stenting for unresectable malignant gastric outlet obstruction (DRA-GOO): a multicentre RCT. #GITwitter #OncTwitter #Endoscopy
2
41
74
Our June issue is now available at including content on NASH cirrhosis, alcohol-related liver disease, irritable bowel syndrome, viral hepatitis, H pylori, eating disorders, inflammatory bowel disease + much more!. #gitwitter #livertwitter #medtwitter
0
27
74
New research - Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial - #SoMe4Surgery #IBD #crohns #crohnsdisease #GITwitter
1
44
74
1
47
72
Today is #InternationalNASHDay - revisit our recent Editorial on redefining non-alcoholic fatty liver disease: what's in a name?. #NAFLD #NASH #fattyliver #MASH #MAFLD #livertwitter #free
2
33
72
New Personal View online—Jalleh et al discuss the gastrointestinal effects of #GLP1 receptor agonists, considerations and recommendations for surgery and endoscopy in patients on GLP1s, and priorities for future research. 📄 #GITwitter
2
22
69
New online - #SARSCoV2 #vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology #IBD section and #IBD Clinical Research Group position statement. @BritSocGastro @NickPowellLab @charlie_lees.@CrohnsColitisUK
2
50
69
Mental disorders frequently co-occur with irritable bowel syndrome. Read more in this Viewpoint on the common mental disorders #anxiety and #depression in #IBS by @hmstaudacher @AntMikocka & @alex_ford12399 . #WorldMentalHealthDay #GITwitter.
0
30
67
In our latest issue - Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. #GITwitter #LiverTwitter #SoMe4Surgery #TransplantTwitter @IHPBA @gbonneysurg #crcsm
2
40
68
New research @TheLancet - @babudayyeh et al - Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a multicentre, randomised trial. #endoscopy #gastroplasty #obesity #gitwitter
1
23
68
New Viewpoint - Shiha et al - Redefining fatty liver disease: an international patient perspective. #NAFLD #MAFLD #fattyliver #livertwitter @EuropeLiver @Hep_Alliance @asscatinforma @ECPObesity
1
33
68
New research - Lee et al - Trastuzumab plus FOLFOX for HER2-positive #biliarytractcancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14). #gitwitter #onctwitter @oncoalert
0
27
64
Rohit Loomba @DrLoomba kicks things off in the late breakers session at #ILC2022 with data from a phase 2 RCT of semaglutide 2.4 mg once weekly for patients with #NASH-related #cirrhosis #livertwitter
2
12
65
New research - Targher et al - Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. #livertwitter #fattyliver #CVD #NAFLD
1
29
62
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: the prospective, multicentre PANTS cohort study - #crohnsdisease #crohns #IBD
2
49
62
9 in 10 cases of liver disease have preventable causes. Our new Editorial explores the latest sobering data from @OHID that reveal sharp rises in hospital admissions due to liver disease in England .#livertwitter .
1
25
65
New Research - Morris et al - Impact of the #COVID19 pandemic on the detection and management of #colorectalcancer in England: a population-based study. #crcsm @EJAMorris @Oxford_NDPH @UniofOxford @CR_UK @NHSDigital
3
32
60
New @TheLancet - Verrastro et al - Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. #NASH #NAFLD #fattyliver #livertwitter
2
35
61
Anand Kulkarni presents data from the STASH trial of dose tapering vs fixed dose corticosteroids in patients with severe alcohol-associated hepatitis #TLM24 #LiverTwitter
1
26
62
Bruce Sands presents results from the head-to-head SEAVUE randomised trial of ustekinumab vs adalimumab for induction and maintenance in moderate-to-severe #Crohns disease #DDW2021 #gitwitter #IBD
1
23
62
New Review - Shribman et al - Investigation and management of Wilson's disease: a practical guide from the British Association for the Study of the Liver. #wilsonsdisease #LiverTwitter @tom_marjot @BASLedu @BritSocGastro @theABN_Info
0
22
61
New research - Choy et al Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. #IBD #GITwitter @DrMattChoy @DrChrisLi
2
29
61
New research - Louis et al - Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn’s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. #IBD #GITwitter #medtwitter
1
19
62
New Comment - Enteric involvement of coronaviruses: is faecal–oral transmission of #SARSCoV2 possible?. #COVID19 #coronavirus
0
50
54
New Viewpoint - Geldof et al - Classifying perianal fistulising Crohn’s disease: an expert consensus to guide decision-making in daily practice and clinical trials. #Crohns #fistula #IBD #GITwitter @GeldofJeroen @Nusiqbal @philtozer1 @DrAilsaHart
1
26
60
New review - Massironi et al - Inflammation and malnutrition in inflammatory bowel disease. @saramassironi @PeyrinBiroulet @silvio_silvio75 #gitwitter #IBD #malnutrition #inflammation
3
20
57
Today we publish reviews from experts in the Middle East + North Africa and from Latin America on redefining non-alcoholic #fattyliver disease (#NAFLD). NAFLD prevalence is higher in these regions than elsewhere in the world.
1
21
57
New research - Wang et al - Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. #GITwitter #OncTwitter @IARCWHO
8
31
57
New research - Huang et al - Type 2 diabetes, hepatic decompensation & hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. #LiverTwitter #Diabetes #NAFLD #MASLD
6
30
59
On #WorldObesityDay we highlight recent calls to rename and redefine #NAFLD - the most prevalent chronic liver disease, associated with #obesity, as metabolic-associated fatty liver disease (#MAFLD). An international patient.perspective - #fattyliver
1
22
54
Our latest issue is now available at . Topics covered includes AI in colonoscopy, colorectal surgery, pancreatic cancer, natural history of MASLD, GI effects of GLP-1 receptor agonists + more. #GITwitter #LiverTwitter #MedTwitter
1
26
56
New Research - Nguyen et al - Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden - #GITwitter #IBD #ulcerativecolitis #crohns #crohnsdisease
1
24
53
New research - D’Haens et al - Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial. . #GITwitter #IBD
0
25
56
New research - Danese et al - Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. #ulcerativecolitis #IBD #T2T #GITwitter @silvio_silvio75
3
20
54
As the world-leading gastroenterology & hepatology research journal, we publish the best science in our fields. While a partial measurement of our reputation, we are delighted to share our Impact Factor of 45·042.
4
3
55
Radiological intervention (TIPS or BRTO) as secondary prophylaxis for gastric variceal haemorrhage reduced rebleeding but did not improve survival vs serial endoscopic injection sclerotherapy in the CRISP GV randomised trial. #TLM2023 #TLM23 #LiverTwitter
3
15
54
In our latest issue - Treatment of #pouchitis, #Crohn's disease, #cuffitis, and other inflammatory disorders of the #pouch: consensus guidelines from the International Ileal Pouch Consortium. #GITwitter
1
19
55
New research - Loras et al - Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn’s disease (ProtDilat study): an open-label, multicentre, randomised trial. #GITwitter #Crohns #IBD @geteccu #endoscopy
5
25
55
New @TheLancet - Qin et al - Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. #LiverTwitter #OncTwitter #LiverCancer #HCC
0
19
55
New Review - @tom_marjot et al - Sleep and liver disease: a bidirectional relationship. #sleep #liver #livertwitter @Drfattyliver
2
21
54
Our latest issue is now live at with new content about #NAFLD, #CVD, #endoscopy, #livertransplantation, #colorectalcancer, #GIBleeding, #cholangiocarcinoma + more! . #GITwitter #LiverTwitter #MedTwitter
0
15
53
New research - Ovadia et al - Ursodeoxycholic acid in intrahepatic #cholestasis of #pregnancy: a systematic review and individual participant data meta-analysis . @CarolineOvadia @jennasaj @CathWilliamson5 #ICP #livertwitter @NIHRresearch @KingsCollegeLon
2
17
52
Our latest issue is out now at . Content includes non-celiac gluten sensitivity, EUS-guided gastroenterostomy, treatments for Crohn's & faecal incontinence, NAFLD & cancer risk, & managing cirrhosis is limited-resource settings. #GITwitter #LiverTwitter
2
18
51
New research - five trials of etrolizumab for moderately to severely active ulcerative colitis. HIBISCUS I & II - GARDENIA - HICKORY - LAUREL - #GItwitter #IBD #ulcerativecolitis.
1
20
50
New research - Sebastian et al - Assessment, endoscopy, and treatment in patients with acute severe #ulcerativecolitis during the #COVID19 pandemic: the PROTECT-ASUC study. #IBD #ASUC #PROTECTASUC @ibdseb @DrNickKennedy @DrChrisLamb @CrohnsColitisUK
1
25
53
We are indexed in the Web of Science Core Collection (ESCI), MEDLINE/PubMed, Embase, and Scopus—consider us for publication. Visit for more information.
0
14
49
New Comment - Israelsen et al - MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. #LiverTwitter #MetALD @IsraelsenMads @AleksanderKrag @MajaThiele
1
29
54
New Review - Bo Shen et al - Treatment of pouchitis, Crohn’s disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. #GITwitter #pouch #ilealpouch
1
23
53